Journal of the Korean Association of Oral and Maxillofacial Surgeons

  • 제36권6호
  • /
  • Pages.508-514
  • /
  • 2010
  • /
  • 2234-7550(pISSN)
  • /
  • 2234-5930(eISSN)
대한구강악안면외과학회 (The Korean Association of Oral and Maxillofacial Surgeons)
권호 표지
DOI QR코드

DOI QR Code

경구 bisphosphonate를 복용하는 환자에서 발생한 bisphosphonate-related osteonecrosis of jaw에 대한 임상적 특징 및 처치: 증례보고

Clinical feature and treatment of bisphosphonate-related osteonecrosis of jaw about oral bisphosphonate administrated patients: case reports

  • 최우성 (가톨릭대학교 여의도 성모병원 구강악안면외과) ;
  • 윤현중 (가톨릭대학교 여의도 성모병원 구강악안면외과) ;
  • 이상화 (가톨릭대학교 여의도 성모병원 구강악안면외과)
  • Choi, Woo-Sung (Department of Oral and Maxillofacial Surgery, Yeouido St. Mary's Hospital, The Catholic University of Korea) ;
  • Yoon, Hyun-Joong (Department of Oral and Maxillofacial Surgery, Yeouido St. Mary's Hospital, The Catholic University of Korea) ;
  • Lee, Sang-Hwa (Department of Oral and Maxillofacial Surgery, Yeouido St. Mary's Hospital, The Catholic University of Korea)
  • 투고 : 2010.08.05
  • 심사 : 2010.12.15
  • 발행 : 2010.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Bisphosphonates are used effectively for many medical conditions, such as multiple myeloma, Paget's disease, osteoporosis, etc. However, recently, osteonecrosis of the jaw was observed in patients receiving long-term bisphosphonate therapy, including oral administration. This osteonecrosis is refractory, and complete recovery is not guaranteed despite a standard treatment protocol being established by many associations related to oral and maxillofacial surgery. The treatment outcome of oral bisphosphonate-related osteonecrosis of jaw (BRONJ) is reported with a review of the relevant literature.

키워드

참고문헌

  1. Ashcroft AJ, Davies FE, Morgan GJ. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 2003;4:284-92. https://doi.org/10.1016/S1470-2045(03)01076-3
  2. Delmas PD, Meunier PJ. The management of Paget's disease of bone. N Engl J Med 1997;336:558-66. https://doi.org/10.1056/NEJM199702203360807
  3. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57. https://doi.org/10.1200/JCO.2003.08.017
  4. Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology 2005;66: 658.
  5. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21. https://doi.org/10.1002/cncr.20308
  6. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44:857-69. https://doi.org/10.1016/j.oraloncology.2007.11.012
  7. Fleisch H. Bisphosphonates in osteoporosis. Eur Spine J 2003;12 Suppl 2:S142-6.
  8. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005;20:977-86. https://doi.org/10.1359/JBMR.050109
  9. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 Update. J Oral Maxillofac Surg 2009;67(5 Suppl):2-12. https://doi.org/10.1016/j.joms.2009.01.009
  10. Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-belated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(5 Suppl):85-95. https://doi.org/10.1016/j.joms.2009.01.006
  11. Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg 2010; 39:251-5. https://doi.org/10.1016/j.ijom.2009.11.014
  12. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1
  13. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62: 527-34. https://doi.org/10.1016/j.joms.2004.02.004
  14. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-41. https://doi.org/10.1016/j.tripleo.2006.06.004
  15. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75. https://doi.org/10.1016/j.joms.2005.07.010
  16. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61. https://doi.org/10.7326/0003-4819-144-10-200605160-00009
  17. Chaudhry AN, Ruggiero SL. Osteonecrosis and bisphosphonates in oral and maxillofacial surgery. Oral Maxillofacial Surg Clin North Am 2007;19:199-206, vi. https://doi.org/10.1016/j.coms.2007.01.005
  18. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24: 945-52. https://doi.org/10.1200/JCO.2005.04.2465
  19. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23. https://doi.org/10.1016/j.joms.2006.10.061
  20. Harper R, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH (1-34)]. J Oral Maxillofac Surg 2007;65:573-80. https://doi.org/10.1016/j.joms.2006.10.076
  21. Adornato M, Morcos I, Rozanski J. The treatment of bisphosphonate- associated osteonecrosis of the jaws with bone resection and autogenous platelet-derived growth factors. J Am Dent Assoc 2007;138:971-7. https://doi.org/10.14219/jada.archive.2007.0294
  22. Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(5 Suppl):96-106. https://doi.org/10.1016/j.joms.2008.12.003